Raltegravir
Thông số
518048-05-0Số CAS
610-733-3Số EC
N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamideTên IUPAC
C20H21FN6O5Công thức hóa học
444.4 g/molKhối lượng phân tử
Raltegravir; 518048-05-0; MK-0518; MK0518; raltegravirum; DTXSID2048660; MK 0518; N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; CHEBI:82960; 22VKV8053U; 4-Pyrimidinecarboxamide, N-((4-fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-; DTXCID5028586; L000900612; L-000900612; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-; N-(2-(4-((4-fluorophenyl)methylcarbamoyl)-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; RefChem:55964; J05AX08; 0518, MK; Raltegravir (MK-0518); N-(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; Raltegravir (INN); MFCD10698872; C20H21FN6O5; NCGC00184997-01; RALTEGRAVIR [INN]; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; Isentress(TM); N-[1-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxo-pyrimidin-2-yl]-1-methyl-ethyl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; CAS-518048-05-0; Raltegravir [USAN:INN]; UNII-22VKV8053U; Raltegravir?; HSDB 8124; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide; RLT; 518048-05-0 (free); RALTEGRAVIR [MI]; Raltegravir(MK-0518); Raltegravir; MK-0518; Epitope ID:231726; K-0518; RALTEGRAVIR [VANDF]; RALTEGRAVIR [MART.]; hydropyrimidine-4-carboxamide; SCHEMBL51817; RALTEGRAVIR [WHO-DD]; MLS006011985; SCHEMBL996804; RALTEGRAVIR [EMA EPAR]; CHEMBL254316; orb1224836; orb1305950; SCHEMBL2112870; Raltegravir - Bio-X trade mark; BDBM25351; GTPL11571; CZFFBEXEKNGXKS-UHFFFAOYSA-N; GLXC-90212; HMS3655B09; HMS5080N13; EX-A2147; Tox21_113019; EBC-07544; NSC762522; s2005; T2239L; AKOS015902444; AKOS025149884; AKOS032960305; Tox21_113019_1; AC-5261; CCG-269170; DB06817; FR29048; NSC-762522; PB13312; SB20935; NCGC00274066-01; NCGC00274066-05; AS-16992; BR164312; HY-10353; SMR003601806; NS00015450; R0247; SW220138-1; D06676; EN300-120882; yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; AB01566833_01; F547236; Q421552; BRD-K05658747-001-02-9; BRD-K05658747-001-03-7; BRD-K05658747-237-01-1; [(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-; Z1532717445; N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo -4-pyrimidinecarboxamide; N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide; N-(2-(4-(4-FLUOROBENZYLCARBAMOYL)-5-HYDROXY-1-METHYL-6-OXO-1,6- DIHYDROPYRIMIDIN-2-YL)PROPAN-2-YL)-5-METHYL-1,3,4-OXADIAZOLE-2-CARBOXAMIDE; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-OH-1-Me-6-oxo-pyrimidin-2-yl)propan-2-yl)-5-Me-1,3,4-oxadiazole-2-carboxamide; N-(4-FLUOROBENZYL)-5-HYDROXY-1-METHYL-2-(1-METHYL-1-(((5-METHYL-1,3,4-OXADIAZOL-2-YL)CARBONYL)AMINO)ETHYL)-6-OXO-1,6-DIHYDROPYRIMIDINE-4-CARBOXAMIDE; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; N-[(4-Fluorophenyl)methyl]-5-hydroxy-1-methyl-2-[2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide; N-[2-(4-{[(4-fluorophenyl)methyl]carbamoyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamideTên gọi khác
Sản phẩm chứa Raltegravir
ISENTRESS 600 MG COMPRIMIDOS RECUBIERTOS CON PELICULAISENTRESS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULAISENTRESS 25 MG COMPRIMIDOS MASTICABLESISENTRESS 100 MG COMPRIMIDOS MASTICABLESIsentressRaltegravir Tablets 400mgRaltegravirRALTEGRAVIR CAS 518048-05-0 INTERMEDIATESRaltegravirRaltegravirRaltegravirRALTEGRAVIR
